The Future of Cannabis Is In Rare Cannabinoids
The future of cannabis is in rare cannabinoids such as CBG, CBN, THCV, THCA, and more, said Dennis O’Neill, president of BioMedican, a biotech company that has developed a unique patented method of producing pharmaceutical-grade cannabinoids.
“These rare cannabinoids offer specific health benefits that are better than CBD,” O’Neill said.
O’Neill explained that CBD, while a booming industry with applications to numerous industries like pharmaceuticals, food and beverage, health products, etc., the traditional method of producing cannabinoids through plants is a costly and cumbersome process, with short production cycles and limited yields.
BioMedican’s biosynthesis process, on the other hand, promises a more controllable method of production than growing plants. In addition, with the biosynthesis process companies will be able to produce expensive and rare cannabinoids at a much lower price and without fears of contamination. BioMedican is headquartered in Fremont, California.
Psychedelics’ Role in Mental Health Issues
O’Neill also talked about the rise in mental health issues during the pandemic and noted that pilot studies currently underway are looking at the mental health applications of psychedelics.
“Mental health issues are a problem as the pandemic continues and traditional medications are not doing the trick,” he said. “There is a lot of evidence that psychedelics may be able to treat some of these mental disorders.”
Indeed, the New York Times recently reported that MDMA, known as Ecstasy or Molly, was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy. This is an important step toward medical approval.
Listen to this fascinating interview The Future of Cannabis Is In Rare Cannabinoids with BioMedican’s Dennis O’Neill and let us know what you think on one of our social media sites:
LinkedIn: https://www.linkedin.com/in/paxton-quigley-0ba439/ Webpage: https://www.paxtonquigley.com/